top of page

About Us

History

StemInov is a clinical stage company, spin-off from Nancy’s Teaching Hospital and Lorraine Region’s Uni.

The company develops an off-the-shelf, allogenic stem cell therapy treatment, in the field of inflammatory pathologies, with a focus on critical care.

The company's lead product candidate “WhartSep” is based on Stem cells from Wharton jelly of the umbilical cord (WJ-MSC) and classified by the EMA (European Medicines Agency) as an ATMP (Advanced-Therapy Medicinal Product).

WhartSep is a new concept in immunomodulation and adaptive medicine thanks to its immunomodulation properties.

Our first indication is the patented treatment of septic shock and ARDS in entry of phase I/IIa

Technology

Capture d’écran 2022-10-24 à 17.46.23.png

Management Team

Consultants

STRATEGY

Eric HALIOUA

Eric is a serial entrepreneur who combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising.  He is the CEO of PDC line Pharma

CMC

Claude DEDRY

Industrial Pharmacist

Cell Production GMP Unit Expert

CMC expert in cell and gene therapy

Several GMP accreditations

CLINICAL STRATEGY

Pierre Emmanuel CHARLES

Prof. in an Intensive Care Unit of a University Hospital. In charge of  designing and conducting experimental and translational research towards sepsis

REGULATORY AFFAIRS

Roland GORDON BERESFORD

Expert in regulatory affair with experience in ATMP

Intellectual Property management

​

bottom of page